concerning selleck compound These experiments Inhibitors,Modulators,Libraries provide the rationale for a promising new therapeutic approach for the treatment selleck inhibitor of therapy resistant rhabdoid tumors. Background Endometrial cancer is one of the most common gy necological cancers in the world and accounts for approximately 50,000 deaths worldwide each year. Patients with tumor confined to the uterus are treated with surgery and radiotherapy. Inhibitors,Modulators,Libraries However, more than 25% of patients diagnosed with endometrial car Inhibitors,Modulators,Libraries cinoma have an invasive Inhibitors,Modulators,Libraries primary cancer accompanied by metastases. Despite treatment with aggressive che motherapeutic regimens, these patients have a 5 year survival rate of less than 20%.

In fact, metastasis represents the main cause of death for patients with endometrial cancer, and the battle against this cancer would greatly benefit from the identification Inhibitors,Modulators,Libraries of factors Inhibitors,Modulators,Libraries involved in the metastatic process.

Certain cases of endometrial Inhibitors,Modulators,Libraries cancer with a particular morphology, ad verse histopathological features or Inhibitors,Modulators,Libraries advanced stage are characterized by aggressive behavior Inhibitors,Modulators,Libraries and poor progno sis. The molecular pathogenesis of endometrial Inhibitors,Modulators,Libraries can cer remains poorly understood, resulting in a limited cure rate in the treatment of advanced cases. Thus, new therapeutic approaches are needed for advanced or re lapsed disease. The hypothalamic peptide GnRH plays an important role in the maintenance of intrauterine tissues and the development of endometrial cancer.

Inhibitors,Modulators,Libraries In mammals, GnRH II is more widely present in peripheral tissues than GnRH I, which suggests that GnRH II may have additional functions.

GnRH II has been shown to have direct antiproliferative effects in the growth of endometrial cancer cells. Inhibitors,Modulators,Libraries These find ings raise the possibility that GnRH II could directly regulate the tumor progression of endometrial cancer cells. Inhibitors,Modulators,Libraries The role of GnRH II in endometrial cancer cell invasion is not known, and the mechanism by which GnRH II regulates Inhibitors,Modulators,Libraries the invasiveness of endometrial tu mors has also not been established. The MAPKs are considered to be important the following site components of GnRH induced signaling pathways in various cell types.

We have previously demonstrated that the anti proliferative effect of GnRH II is mediated Inhibitors,Modulators,Libraries by the MAPKs signalings. Different mechanisms have been suggested for MAPK activation through GPCRs.

MMPs are largely implicated in promoting angiogenesis and tumor metastasis. Some evi dence indicates an expanded role for GnRH in certain aspects selleck catalog of gynecologic tumor progression, such as me tastasis, via the activation of MMPs and the subsequent all targets increase in cell migration and invasion. In the present study, we examined the effect of a GnRH II agonist on the motility of endometrial cancer cells and the mechanisms of the action involved.